Abstract
Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Recent Patents on Anti-Cancer Drug Discovery
Title: Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Volume: 4 Issue: 3
Author(s): Chirag M. Shah
Affiliation:
Keywords: Amrubicin, small cell, lung cancer, chemotherapy, synthetic anthracyclin
Abstract: Amrubicin is a synthetic anthracyclin analogue that has significant activity in Japanese patients with extensive stage small cell lung cancer (ES-SCLC). There has not been significant advances made in the treatment of this disease in last several years and new therapies are desperately needed to change the natural history of this disease. Preliminary data has shown that amrubicin possesses anti-tumor activity in patients with extensive stage small cell lung cancer in the western population. Clinical trials are on going to evaluate this agent further in Europe and US. If effective, it may be an invaluable addition into the current armamentarium to treat this deadly disease. The review includes patent coverage on the treatment of small cell lung cancer.
Export Options
About this article
Cite this article as:
Shah M. Chirag, Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206850
DOI https://dx.doi.org/10.2174/157489209789206850 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry Steroidal Cardiac Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors Exhibit Strong Anti-Cancer Potential <i>in vitro</i> and in Prostate and Lung Cancer Xenografts <i>in vivo</i>
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors: From Chromatin Remodeling to Experimental Cancer Therapeutics
Current Medicinal Chemistry Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Hybrid Imaging: Conclusions and Perspectives
Current Medical Imaging Anticancer Drug Combinations, How Far We can Go Through?
Anti-Cancer Agents in Medicinal Chemistry microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?
Current Cancer Drug Targets Weight Optimized Neural Network Using Metaheuristics for the Classification of Large Cell Carcinoma and Adenocarcinoma from Lung Imaging
Current Signal Transduction Therapy PET Tracers Based on Zirconium-89
Current Radiopharmaceuticals NSCLC Structure-activity Relationship (SAR) Study of Diisothiocyanates for Antiproliferative Activity on A549 Human Non-small Cell Lung Carcinoma (NSCLC)
Letters in Organic Chemistry Practical Aspects in the Use of Biomarkers for the Development of Cancer Vaccines
Current Cancer Therapy Reviews Peptide-Drug Conjugate: A Novel Drug Design Approach
Current Medicinal Chemistry Opposing Functions for the Wilms Tumor Protein 1 (WT1) in Tumorigenesis
Current Pediatric Reviews Deubiquitinating Enzymes as Promising Drug Targets for Infectious Diseases
Current Pharmaceutical Design Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Synthetic Lethality: From Research to Precision Cancer Nanomedicine
Current Cancer Drug Targets Tumorspheres Derived from HCC Cells are Enriched with Cancer Stem Cell-like Cells and Present High Chemoresistance Dependent on the Akt Pathway
Anti-Cancer Agents in Medicinal Chemistry